Acurian Inc.
This article was originally published in Start Up
Executive Summary
Acurian's management believes it targets perhaps the most direct and concrete opportunity to significantly reduce the time it takes to bring a drug to market: the recruitment of patients and physician investigators for clinical trials. Acurian offers web-based solutions designed to help pharmaceutical and biotech companies increase the efficiency of matching patients and investigators to appropriate trials.
You may also be interested in...
Clinical Trial Recruitment: e-Recruiters Out, Pharma Consortium In?
A recent Forrester Research report predicts that a consortium of major pharmaceutical companies will form to address the inefficiencies--and resulting delays--in the clinical trial recruitment process. Forrester's Michael Barrett also says that the business model of the current crop of e-recruiting start-up companies (which largely depends on performance-based compensation) is not sustainable, and that that the future for them is as fee-for-service sub-contractors to the consortium. But most industry observers probably aren't quite ready to accept the notion that the fiercely competitive drug industry is about to become clubby when it comes to trial recruitment.
AureoGen Biosciences Inc.
Formed by Kalamazoo-based Pharmacia alumni, AureoGen Biosciences Inc. is genetically engineering cyclic peptides to create second-generation, resistance-proof anti-infective and anti-fungal therapeutics.
Pain Therapeutics
Pain seems as close to a sure bet as the pharmaceutical industry has to offer. Forecasts call for the worldwide analgesic market, already $38 billion in 2002, to grow at a 20% annual clip, nearly doubling to $75 billion by the year 2010. For new drug developers, pain also has the advantage of offering clearly definable endpoints-less pain-and a relatively short duration for clinical trials. No surprise then that more than 200 companies have a hand in developing or marketing pain therapeutics. Among them, the three young companies profiled here-AlgoRx Pharmaceuticals Inc., Algos Therapeutics Inc., and TheraQuest Biosciences LLC.